NTT-DOCOMO
NTT DOCOMO, INC. announced today that it will unveil a number of world-first technologies among a total of 31 innovative technologies for 5G Evolution, 6G, Generative AI and more during docomo Open House'24, an exhibition of cutting-edge technological advancements to be held in Tokyo on January 17 and 18.
A dedicated website (https://docomo-openhouse24.smktg.jp/public/application/add/32) will be accessible from January 17 until February 29 to showcase the exhibits, including highlights such as the following.
5G Evolution & 6G
Sub-terahertz bandwidth for ultra-high-capacity communication over 100Gbps
Cutting-edge technologies such as extreme-high-speed transmissions over 100Gbps, together with AI, will be deployed to meet the advanced requirements of 6G in the coming future. As one example, DOCOMO will launch new communication infrastructure to harness sub-terahertz bandwidths for the integration of physical space and cyberspace.
https://docomo-openhouse24.smktg.jp/public/session/view/97
FEEL TECH® for sharing sensory perceptions via human-augmentation platform
FEEL TECH® is the world's first technology for sharing taste sensations between individuals via DOCOMO's human-augmentation mobile platform. It is expected to be used in the metaverse, as well as in movies and animations, to incorporate taste expressions into extra-rich content that people will experience with an immersive sense of presence.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1221_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/76
Network technology for non-terrestrial areas, including air, sea and space
In the future, networks incorporating high-altitude platform stations (HAPS) will support disaster communications, ship and drone connectivity, and communications in mountainous and remote areas. The exhibit will showcase the latest technologies for non-terrestrial network (NTN) HAPS and underwater drones for mobile coverage beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1207_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/101
Next-generation cloud slicing and 5GC on AWS to meet specific network needs
Tailoring networks to meet specific quality-of-service requirements remains a challenge. This innovative solution combines end-to-end orchestration, QoS visualization and monitoring, and 5G Core from AWS to deliver flexible network quality for specific locations and time scenarios. By integrating the cloud, energy efficiency and on-demand network quality, the solution will help realize highly sustainable networks.
https://docomo-openhouse24.smktg.jp/public/session/view/69
5G application to address diverse mobile needs in industrial settings
The adoption of 5G in the industrial sector is still limited. More extensive 5G implementation in the industrial world will require comprehensive analysis and multi-dimensional verification that can address diverse mobile needs and environments. DOCOMO has developed an advanced yet portable simulator that makes it easy to visualize 5G wireless transmission characteristics and electromagnetic interference effects in each customer's unique industrial setting.
https://docomo-openhouse24.smktg.jp/public/session/view/107
Generative AI
Enlivening the metaverse with generative AI that creates non-player characters
The world-first technology from DOCOMO uses generative AI to create non-player characters in the metaverse. The innovative technology, which automatically generates each character's appearance, behavior and role to eliminate the need for experts with specialized know-how, will help realize more enriched metaverse experiences in the future.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_01.html
https://docomo-openhouse24.smktg.jp/public/session/view/67
DOCOMO will also showcase a selection of the above technologies at MWC Barcelona 2024 from February 26 to 29.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_00.html
Permission granted for the use of copyrighted images.
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116271722/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom